XSHG
603880
Market cap357mUSD
Oct 09, Last price
8.56CNY
1D
3.26%
1Q
20.56%
IPO
31.65%
Name
Jiangsu Nanfang Medical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1990 in Changzhou, China, Jiangsu Nanfang Medical Co., Ltd. is dedicated to the innovation, production, and worldwide distribution of a comprehensive range of medical and healthcare products. Their offerings span transdermal solutions, specialized medical textiles, various adhesive tapes, bandages, sports injury prevention items, first-aid essentials, and personal care products. The company's extensive inventory includes a variety of medical and surgical adhesive tapes, advanced wound care dressings, and specialized plasters like capsicum, corn removal, and waterproof options. They also provide therapeutic products such as physical therapy and kinesiology tapes, rigid sports tapes, pain relief patches and sleeves, medical eye pads, elastic stretch tapes, and zinc oxide adhesive plasters, in addition to masks and custom-made solutions.
Key people
Lingfeng He
Executive Chairman of the Board, Acting Finance Director, General Manager · since 2025
Linye Xu
Deputy General Manager, Secretary of the Board, Director · since 2025
Caiying Hu
Staff Elected Director · since 2025
Binbin Shen
Director · since 2026
Qinhua Xiang
Chief Financial Officer, Director, Finance Manager
Xiao Xu
Director · since 2025
Independent Director · since 2025
Jun Zhang
Independent Director · since 2025
Yu Zheng
Independent Director · since 2025
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||